Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis

Critical Care Clinics

Volumn 18, Issue 4, 2002, Pages 855-879

  Frankel, Stephen K ^a,b   Sullivan, Eugene J ^c   Brown, Kevin K ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; T LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR; VIDARABINE;

ACUTE GLOMERULONEPHRITIS; ADRENAL SUPPRESSION; AORTA ARCH SYNDROME; ATHEROSCLEROSIS; AVASCULAR NECROSIS; CATARACT; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DEPRESSION; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM ULCER; DISEASE CLASSIFICATION; EDEMA; EUPHORIA; FATIGUE; GLAUCOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; INSOMNIA; LUNG HEMORRHAGE; MALAISE; MYOPATHY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATHOGENESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SMALL VESSEL VASCULITIS; VASCULITIS; WEGENER GRANULOMATOSIS; WEIGHT GAIN;

CHURG-STRAUSS SYNDROME; HUMANS; POLYARTERITIS NODOSA; TAKAYASU'S ARTERITIS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0036839354     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(02)00031-3     Document Type: Review

References (151)

1. Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis: Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population based data sources. Arthritis Rheum 1996;39:87-92.
2. Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997: Clinical and epidemiologic aspects. Medicine (Baltimore) 1999;78:292-308.
3. Haugeberg G, Bie R, Bendvold A. Primary vasculitis in a Norwegian community hospital: A retrospective study. Clin Rheumatol 1998;17:364-8.
4. Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. Arthritis Rheum 2000;43:414-9.
5. Conron M, Beynon HLC. Churg-Strauss syndrome. Thorax 2000;55:870-7.
6. Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342:651-2.
7. Guillevin L, Lhote F, Gherardi R. The spectrum and treatment of virus-associated vasculitides. Curr Opin Rheumatol 1997;9:31-6.
8. Jennette JC, Falk RJ. Small-vessel vasculitis. New Engl J Med 1997;337:1512-23.
9. Kawachi Y, Nukaga H, Hoshino M, et al. ANCA-associated vasculitis and lupus-like syndrome caused by methimazole. Clin Exp Dermatol 1995;20:345-7.
10. Specks U. Pulmonary vasculitis. In: Schwarz MI, King TE, editors. Intersitial Lung Disease. 3rd Edition. Hamilton (ON): B.C. Decker; 1998. p. 507-34.
11. van den Bogaerde J, Beynon HLC. Pulmonary vasculitis and rheumatic diseases. Semin Respir Rit Care Med 1998;19:57-67.
12. Jennette JC, Falk RJ. Clinical and pathological classification of ANCA-associated vasculitis: What are the controversies? Clin Exp Immunol 1995;101(Suppl 1):18-22.
13. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
14. Jennette JC, Falk R, Andrassay K, et al. Nomemclature of systemic vasculitides. Arthritis Rheum 1990;37:187-92.
15. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
16. Lightfoot RW, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-93.
17. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis. Arthritis Rheum 1990;33:1094-100.
18. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagosis of vasculitis. Ann Intern Med 1998;129:345-52.
19. Sorensen SF, Slot O, Tvede N, et al. A prospective study of vasculitis patients collected in a five year period: Evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 2000;59:478-82.
20. Zamora MR, Warner ML, Tuder R, et al. Diffuse alveolar hemorrhage and systemic lupus erthematosus (SLE): Clinical presentation, histology, survival and outcome. Medicine (Baltimore) 1997;76:192-202.
21. Green RJ, Ruoss SJ, Kraft SA, et al. Pulmonary capillaritis and alveolar hemorrhage: Update on dignosis and management. Chest 1997;110:1305-16.
22. Schwarz MI. Diffuse alveolar hemorrhage. In: Schwarz MI, King TE, editors. Interstitial Lung Disease. 3rd Edition. Hamilton (ON): B.C. Decker. 1998. p. 535-58.
23. Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax 2000;55:502-10.
24. Bolton WK. Rapidly progressive glomerulonephritis. Semin Nephrol 1996;16:517-26.
25. Couser WG. Glomerulonephritis. Lancet 1999;353:1509-15.
26. Erwig LP, Rees AJ. Rapidily progressive glomerulonephritis. J Nephrol 1999;12(Suppl 2):S111-9.
27. Jennette JC, Falk RJ. Diagnosis and management of glomerulonephritis and vasculitis presenting as acute renal failure. Med Clin North Am 1990;74:893-908.
28. Madaio MP, Harrington JT. The diagnosis of glomerular diseases. Arch Intern Med 2001;161:25-34.
29. Jayne DR. Pulmonary-renal syndrome. Semin Respir Crit Care Med 1998;19:69-77.
30. Niles JL, Bottinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996;156:440-5.
31. Saxena R, Bygren P, Arvastsin B, et al. Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome Intern Med 1995;238:143-52.
32. Jayne D. Update on the European Vasculitis Study Group Trials. Curr Opin Rheumatol 2001;13:48-55.
33. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:66-75.
34. Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. Q J Med 1993;86:779-89.
35. Guillevin L. Treatment of classic polyarteritis nodosa in 1999. Nephrol Dial Transplant 1999;14:2077-9.
36. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu's arteritis. Ann Intern Med 1994;120:919-29.
37. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Arthritis Rheum 2000;43:1021-32.
38. Adu D, Howie AJ, Scott DG, et al. Polyarteritis and the kidney. Q J Med 1987;62:221-37.
39. Hogan SL, Nachman PH, Wilkman AS, et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32.
40. Matteson EL, Gold KN, Bloch DA, et al. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis criteria cohort. Am J Med 1996;101:129-34.
41. Romas E, Murphy BF, d'Apice AJ, et al. Wegener's granulomatosis: Clinical features and prognosis in 37 patients. Aust N Z J Med 1993;23:8-75.
42. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989;32:45-53.
43. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989;11:954-63.
44. Davies DJ, Moran JE, Niall JF, et al. Segemental necrotizing glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology? BMJ 1982;285:606.
45. Van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1(8426):425-9.
46. Choi HK, Liu S, Merkel PA, et al. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: Metaanalysis with a focus on myeloperoxidase antibodies. J Rheumatol 2001;28:1584-90.
47. Cohen-Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149:2461-5.
48. Gross WL. Antineutrophil cystoplasmic autoantibody testing in vasculitides. Rheum Dis Clin North Am 1995;21:987-1011.
49. Gross WL, Schnabel A, Tranbandt A. New perspectives in pulmonary angiitis: From pulmonary angiitis and granulomatosis to ANCA associated vasculitis. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:33-52.
50. Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999;111:507-13.
51. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum 2000;43:2025-33.
52. Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Weneger's granulomatosis. Adv Exp Med Biol 1993;336:411-4.
53. Noille B, Specks U, Ludemann J, et al. Anticytoplasmic autoantibodies: Their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 1989;111:28-40.
54. Cohen Tervaert JW, Goldschmeding R, Elema JD, et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 1990;33:1264-72.
55. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis. Arthritis Rheum 1999;42:421-30.
56. Guillevin L, Visser H, Noel LH, et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome - 62 Patients. J Rheumatol 1993;20:1345-9.
57. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53:743-53.
58. Solans R, Bosch JA, Perez-Bocanegra C, et al. Churg-Strauss syndrome: Outcome and longterm follow-up of 32 patients. Rheumatology 2001;40:763-71.
59. Mulder AH, Broekroelofs J, Horst G, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: Characterization and clinical correlates. Clin Exp Immunol 1994;95:490-7.
60. Mulder AH, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993;17:411-7.
61. Mulder AH, Horst G, van Leeuwen MA, et al. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis: Characterization and clinical correlations. Arthritis Rheum 1993;36:1054-60.
62. Schnabel A, Csernok E, Isenberg DA, et al. Antineutrophil cytoplasmic antibodies in systemic antibodies in systemic lupus erythematosus: Prevalence, specificities, and clinical significance. Arthritis Rheum 1995;38:633-7.
63. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 auto-immune hepatitis. Hepatology 1997;25:1105-7.
64. Ara J, Mirapeix E, Rodriguez R, et al. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999;14:1667-72.
65. Cohen P, Guillevin L, Baril L, et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: Follow-up of 53 patients. Clin Exp Rheumatol 1995;13:193-8.
66. Gaskin G, Savage CO, Ryan JJ, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patient with systemic vasculitis. Nephrol Dial Transplant 1991;6:689-94.
67. Jayne DR, Gaskin G, Pusey CD, et al. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995;88:127-33.
68. Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 1997;10:2738-43.
69. Anderson G, Coles ET, Crane M, et al. Wegener's granulomatosis: A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992;83:427-38.
70. Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: Propsective clinical and therapeutic expeience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
71. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 1992;116:488-98.
72. Cordier J-F, Valeyre D, Guillevin L, et al. Pulmonary Wegener's granulomatosis: A clinical and imaging study of 77 cases. Chest 1990;97:902-12.
73. Reuter M, Schnabel A, Wesner F, et al. Pulmonary Wegener's granulomatosis: Correlation between high-resolution CT findings and clinical scoring of disease activity. Chest 1998;114:500-6.
74. Lie JT. Illustrated histopathologic classification criteria for selected vasculitic syndromes. Arthritis Rheum 1990;33:1074-87.
75. Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener's granulomatosis. Am J Surg Pathol 1991;15:315-33
76. Aasarod K, Iversen BM, Hammerstrom J, et al. Wegener's granulomatosis: Clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000;15:611-8.
77. Guillevin L, Cordier JF, Lhote F, et al. A prospective multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
78. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antitrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study. Arthritis Rheum 1998;42:2019-20.
79. Hoffman GS, Leavitt RY, Fleisher TA, et al. Treatment of Wegener's granulomatosis with internmittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:399-402.
80. Mahr A, Girard T, Agher R, et al. Analysis of factors predictive survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rhematology 2001;40:492-8.
81. Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-9.
82. Langford CA, Talar-Williams C, Sneller MC. Us of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000;43:1836-40.
83. Leavitt RY, Hoffman GS, Fauci AS. Response: The role of trimethoprim/sulfamethoxazole in the treatment of Wegener's granulomatosis. Arthritis Rheum 1988;31:1073-4.
84. Ohtake T, Kobayashi S, Honjou Y, et al. Generalized Wegener's granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy. Intern Med 2001;40:666-70.
85. Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
86. Cohen Tervaert JW, Stegeman CA, Kallenberg CG. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Nephrol Hypertens 2001;10:211-7.
87. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-54.
88. Weller PF, Plaut M, Taggart V, et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001;108:175-83.
89. Weschler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000;117:708-13.
90. Weschler ME, Garpestad E, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7.
91. Lanham J, Elkon K, Pusey C, et al. Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984;63:65-81.
92. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome: Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
93. Davidson AG, Thompson PJ, Davies J, et al. Prominent pericardial and myocardial lesions in the Churg-Strauss syndrome (allergic granulomatosis and angiitis). Thorax 1983;38:793-5.
94. Guillevin L, Guittard T, Bletry O, et al. Systemic necrotizing angiitis with asthma: Causes and precipitating factors in 43 cases. Lung 1987;165:165-72.
95. Morgan JM, Raposo L, Gibson DG. Cardiac involvement in Churg-Strauss syndrome shown by electrocardiography. Br Heart J 1989;62:462-6.
96. Cohen-Tervaert JW, Goldschmeding R, Elema JD, et al. Antimyeloperoxidase antibodies in the Churg-Strauss syndrome. Thorax 1991;46:70-1.
97. Buschman DL, Waldron JA, King TE. Churg Strauss pulmonary vasculitis: High resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis 1990;142:458-61.
98. Choi YH, Im J-G, Han BK, et al. Thoracic manifestations of Churg-Strauss syndrome. Chest 2000;117:117-24.
99. Leavitt RY, Fauci AS. Pulmonary vasculitis. Am Rev Respir Dis 1986;134:149-66.
100. Staples CA. Pulmonary angiitis and granulomatosis. Radiol Clin North Am 1991;29:973-82.
101. Worthy SA, Muller NL, Hansell DM, et al. Churg-Strauss syndrome: The spectrum of pulmonary CT findings in 17 patients. Am J Roentgenol 1998;170:297-300.
102. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951;27:277-301.
103. Cottin V, Cordier JF. Churg-Strauss syndrome. Allergy 1999;54:535-51.
104. Katzenstein AL. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung: A review. Am J Clin Pathol 2000;114:767-72.
105. Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Semin Respir Crit Care Med 1998;19:27-45.
106. Akikusa B, Sato T, Ogawa M, et al. Necrotizing alveolar capillaritis in autopsy cases of microscopic polyangiitis: Incidence, histopathologenesis and relationship with systemic vasculitis. Arch Pathol Lab Med 1997;121:144-9.
107. D'Agati V, Chander P, Nash M, et al. Idiopathic microscopic polyarteritis nodosa: Ultrastructural observations on the renal vascular and glomerular lesions. Am J Kidney Dis 1986;7:95-110.
108. Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997;36:1290-7.
109. Guillevin L, Lhote F. Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1998;41:2100-5.
110. Guillevin L, Cevallos R, Durand-Gasselin B, et al. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome: Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris) 1997;148:198-204.
111. Nachman PH, Hogan SL, Jennette JC, et al. Treatment response and relapse in antineutrophil cyctoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:33-9.
112. Boki KA, Dafni U, Karpouzas GA, et al. Necrotizing vasculitis in Greece: Clinical, immunological and immunogenetic aspects: A study 66 patients. Br J Rheumatol 1997;36:1059-66.
113. Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatits B virus. Medicine (Baltimore) 1995;72:238-53.
114. Guillevin L, Lhote F. Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curt Opin Rheumatol 1995;7:20-4.
115. Guillevin L, Houng Du LT, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: A study in 165 patients. Br J Rheumatol 1988;27:258-64.
116. Guillevin L, Lhote F, Amouroux J, et al. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathologic findings in polyarteritis nodosa and churg-strauss syndrome: Indications for the classification of vasculitides of the polyarteritis nodosa group. Br J Rheumatol 1996;35:958-64.
117. Kirkland GS, Savige J, Wilson D, et al. Classical polyarteritis nodosa and microscopic polyarteritis with medium vessel involvement - A comparison of the clinical and laboratory features. Clin Nephrol 1997;47:176-80.
118. Stanson AW, Friese JL, Johnson CM, et al. Polyarteritis nodosa: Spectrum of angiographic findings. Radiographics 2001;21:151-9.
119. Guillevin L, Lhote F, Sauvaget F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994;53:334-7.
120. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and churg-strauss syndrome: A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
121. Fortin P, Larson M, Watters A, et al. Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group: A review of 45 cases. Rheumatol 1995;22:78-84.
122. Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome: A prospective, randomized trial in 78 patients. Arthritis Rheum 1992;35:208-15.
123. Guillevin L, Jarrousse B, Lok C, et al. Long-term follow-up after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange: A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991;18:567-74.
124. Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995;38:1638-45.
125. Cid MC, Font C, Coll-Vinent B, et al. Large vessel vasculitides. Curt Opin Rheumatol 1998;10:18-28.
126. Hall S, Barr W, Lie JT, et al. Takayasu's arteritis: A study of 32 North American patients. Medicine (Baltimore) 1985;64:89-99.
127. Kerr GS. Takayasu's arteritis. Rheum Dis Clin North Am 1995;21:1041-57.
128. Waern AU, Andersson P, Hemmingsson A. Takayasu's arteritis: A hospital region based study on occurrence, treatment and prognosis. Angiology 1983;34:311-26.
129. Hall S, Buchbinder R. Takayasu's arteritis. Rheum Dis Clin North Am 1990;16:411-22.
130. Ishikawa K. Natural history and classification of occlusive thromboaortopathy (Takayasu's disease). Circulation 1978;57:27-35.
131. Lupi-Herrera E, Sanchez-Torres G, Marchusham J, et al. Takayasu's arteritis: Clinical study of 107 cases. Am Heart J 1997;93:94-103.
132. Nakao K, Ikeda M, Kimata S-I, et al. Takayasu's arteritis: Clinical report of eight-four cases and immunological studies of seven cases. Circulation 1967;35:1141-55.
133. Sharma BK, Jain S, Sagar S. Systemic manifestations of Takayasu arteritis: The expanding spectrum. Int J Cardiol 1996;54:S149-54.
134. Sharma BK, Sagar S, Singh AP, et al. Takayasu arteritis in India. Heart Vessels Suppl 1992;7:37-43.
135. Shelhamer JH, Volkman DJ, Parrillo JE, et al. Takayasu's arteritis and its therapy. Ann Intern Med 1985;103:121-6.
136. Moriwaki R, Noda M, Yajima M, et al. Clinical manifestations of Takayasu arteritis in India and Japan. Angiology 1997;48:369-79.
137. Numano F. Differences in clinical presentation and outcome in different countries for Takayasu's arteritis. Curr Opin Rheumatol 1997;9:12-5.
138. Suwanwela N, Piyachon C. Takayasu arteritis in Thailand: Clinical and imaging features. Int J Cardiol 1996;54(Suppl):S117-34.
139. Yamada I, Nakagawa T, Himeno Y, et al. Takayasu arteritis: Diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging 2000;11:481-7.
140. Yamada I, Nakagawa T, Himeno Y, et al. Takayasu arteritis: Evaluation of the thoracic aorta with CT angiography. Radiology 1998;209:103-9.
141. Yamada I, Numano F, Suzuki S. Takayasu's arteritis: Evaluation with MR imaging, Radiology 1993;188:89.
142. Yamada I, Shibuya H, Matsubara O, et al. Pulmonary artery disease in Takayasu's arteritis: Angiographic findings. Am J Roentgenol 1992;159:263-9.
143. Atalay MK, Bluemke DA. Magnetic resonance imaging of large vessel vasculitis. Curr Opin Rheumatol 2001;13:41-7.
144. Choe YH, Han BK, Koh EM, et al. Takayasu's arteritis: Assessment of disease activity with contrast-enhanced MR imaging. Am J Roentgenol 2000;175:505-11.
145. Tanigawa K, Eguchi K, Kitamura Y, et al. Magnetic resonance imaging detection of aortic and pulmonary artery wall thickening in the acute stage of Takayasu arteritis: Improvement of clinical and radiologic findings after steroid therapy. Arthritis Rheum 1992;35:476-80.
146. Vinijchaikul K. Primary arteritis of the aorta and its main branches (Takayasu's arteriopathy): A clinicopathologic autopsy study of eight cases. Am J Med 1967;43:15.
147. Hall S, Hunder GG. Treatment of Takayasu's arteritis. Ann Intern Med 1986;104:288.
148. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37:578-82.
149. Giordano JM, Leavitt RY, Hoffman G, et al. Experience with surgical treatment of Takayasu's disease. Surgery 1991;109:252-8.
150. Sharma BK, Jain S, Bali HK, et al. A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis. Int J Cardiol 2000;75:S147-52.
151. Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: Presentation, pathology and prognosis. Q J Med 1985;56:467-83.